114 related articles for article (PubMed ID: 15197170)
41. Regulation of PDGF-A: a possible mechanism for angiotensin II-induced vascular growth.
Wang DH; Prewitt RL; Beebe SJ
Am J Physiol; 1995 Jul; 269(1 Pt 2):H356-64. PubMed ID: 7631868
[TBL] [Abstract][Full Text] [Related]
42. LRP: role in vascular wall integrity and protection from atherosclerosis.
Boucher P; Gotthardt M; Li WP; Anderson RG; Herz J
Science; 2003 Apr; 300(5617):329-32. PubMed ID: 12690199
[TBL] [Abstract][Full Text] [Related]
43. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo.
Ballinger ML; Osman N; Hashimura K; de Haan JB; Jandeleit-Dahm K; Allen T; Tannock LR; Rutledge JC; Little PJ
J Cell Mol Med; 2010 Jun; 14(6B):1408-18. PubMed ID: 19754668
[TBL] [Abstract][Full Text] [Related]
44. Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells.
Mondorf UF; Geiger H; Herrero M; Zeuzem S; Piiper A
FEBS Lett; 2000 Apr; 472(1):129-32. PubMed ID: 10781819
[TBL] [Abstract][Full Text] [Related]
45. Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening.
Sirois MG; Simons M; Edelman ER
Circulation; 1997 Feb; 95(3):669-76. PubMed ID: 9024156
[TBL] [Abstract][Full Text] [Related]
46. Platelet-derived growth factor mediates angiotensin II-induced DNA synthesis in vascular smooth muscle cells.
Mangiarua EI; Palmer VL; Lloyd LL; McCumbee WD
Arch Physiol Biochem; 1997 Apr; 105(2):151-7. PubMed ID: 9255399
[TBL] [Abstract][Full Text] [Related]
47. ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo.
Castoldi G; Di Gioia CR; Pieruzzi F; D'Orlando C; Van De Greef WM; Busca G; Sperti G; Stella A
Am J Physiol Heart Circ Physiol; 2003 Feb; 284(2):H635-43. PubMed ID: 12388255
[TBL] [Abstract][Full Text] [Related]
48. Pressure mediates angiotensin II-induced arterial hypertrophy and PDGF-A expression.
Parker SB; Wade SS; Prewitt RL
Hypertension; 1998 Sep; 32(3):452-8. PubMed ID: 9740610
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
Pietras K; Ostman A; Sjöquist M; Buchdunger E; Reed RK; Heldin CH; Rubin K
Cancer Res; 2001 Apr; 61(7):2929-34. PubMed ID: 11306470
[TBL] [Abstract][Full Text] [Related]
50. Role of transforming growth factor-beta 1 in the cellular growth response to angiotensin II.
Koibuchi Y; Lee WS; Gibbons GH; Pratt RE
Hypertension; 1993 Jun; 21(6 Pt 2):1046-50. PubMed ID: 8505090
[TBL] [Abstract][Full Text] [Related]
51. Effect of neonatal sympathectomy on the development of structural vascular changes in angiotensin II-treated rats.
Simon G; Csiky B
J Hypertens; 1998 Jan; 16(1):77-84. PubMed ID: 9533420
[TBL] [Abstract][Full Text] [Related]
52. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats.
Kim S; Ohta K; Hamaguchi A; Yukimura T; Miura K; Iwao H
Hypertension; 1995 Jun; 25(6):1252-9. PubMed ID: 7768570
[TBL] [Abstract][Full Text] [Related]
53. Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.
Graciano ML; Mitchell KD
Am J Physiol Renal Physiol; 2012 Jan; 302(1):F60-9. PubMed ID: 21975872
[TBL] [Abstract][Full Text] [Related]
54. K depletion alters angiotensin II receptor expression in vascular smooth muscle cells.
Linas SL; Marzec-Calvert R; Ullian ME
Am J Physiol; 1990 May; 258(5 Pt 1):C849-54. PubMed ID: 2333982
[TBL] [Abstract][Full Text] [Related]
55. Different structural vascular changes in angiotensin II-treated and cold-stressed rats.
Illyes G; Talarico PJ; Simon G
Am J Hypertens; 2000 Jul; 13(7):802-9. PubMed ID: 10933573
[TBL] [Abstract][Full Text] [Related]
56. Preadipocyte apoptosis is prevented by macrophage-conditioned medium in a PDGF-dependent manner.
Molgat AS; Gagnon A; Sorisky A
Am J Physiol Cell Physiol; 2009 Apr; 296(4):C757-65. PubMed ID: 19225164
[TBL] [Abstract][Full Text] [Related]
57. EGF receptor transactivation in angiotensin II and endothelin control of vascular protein synthesis in vivo.
Beaucage P; Moreau P
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S20-3. PubMed ID: 15838279
[TBL] [Abstract][Full Text] [Related]
58. Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy.
Minatsuki S; Miura I; Yao A; Abe H; Muraoka H; Tanaka M; Imamura T; Inaba T; Maki H; Hatano M; Kinugawa K; Yao T; Fukayama M; Nagai R; Komuro I
Int Heart J; 2015; 56(2):245-8. PubMed ID: 25740390
[TBL] [Abstract][Full Text] [Related]
59. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
Taïeb A; Constans J; Mahon FX
Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
[No Abstract] [Full Text] [Related]
60. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing.
Rajkumar VS; Shiwen X; Bostrom M; Leoni P; Muddle J; Ivarsson M; Gerdin B; Denton CP; Bou-Gharios G; Black CM; Abraham DJ
Am J Pathol; 2006 Dec; 169(6):2254-65. PubMed ID: 17148686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
